- In early August 2026, Insulet Corporation reported second-quarter 2026 results showing revenue of US$801.7 million and net income of US$95 million, with basic and diluted EPS of US$1.37, while also trimming full-year 2026 revenue growth guidance to 21%–23% amid softer U.S. Omnipod demand and type 2 retention issues.
- Beneath the headline beat, management highlighted weaker-than-expected utilization and retention among U.S. type 2 diabetes users and ongoing product quality and litigation risks, even as international Omnipod growth accelerated and the company raised its overseas revenue outlook.
- Next, we’ll examine how Insulet’s strong quarter but reduced full-year revenue guidance, driven partly by type 2 retention challenges, reshapes its investment narrative.
Outshine the giants: these 16 early-stage AI stocks could fund your retirement.
Insulet Investment Narrative Recap
To own Insulet, you need to believe that Omnipod can remain a leading automated insulin platform while the company successfully expands beyond its type 1 core, particularly into type 2 and international markets. The key near term catalyst is whether Insulet can stabilize type 2 utilization and retention, which this quarter clearly challenged. The biggest current risk is that product quality issues and related litigation around recent Pod corrections and recalls erode trust and slow future adoption.
For me, the most relevant recent announcement is Insulet’s decision to trim full year 2026 revenue growth guidance to 21% to 23% after Q2 results. That guidance cut explicitly ties back to weaker type 2 retention and softer U.S. Omnipod demand, which directly touches the newer growth engine many investors are focused on, even as international Omnipod trends remain strong and management raises expectations outside the U.S.
Yet behind the strong Q2 headline numbers, investors should also be aware of the ongoing class action tied to multi million unit Pod corrections and recalls...
Read the full narrative on Insulet (it's free!)
Insulet's narrative projects $4.8 billion revenue and $734.9 million earnings by 2029.
Uncover how Insulet's forecasts yield a $235.54 fair value, a 69% upside to its current price.
Exploring Other Perspectives
The lowest ranked analysts were already cautious, assuming revenue of about US$4.6 billion and earnings near US$749 million by 2029, and this type 2 retention setback plus recall overhang could reinforce their concern that execution risks around scaling Omnipod use, especially beyond type 1, might keep outcomes closer to the pessimistic end of expectations rather than the consensus view.
Explore 6 other fair value estimates on Insulet - why the stock might be a potential multi-bagger!
Reach Your Own Conclusion
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Insulet research is our analysis highlighting 4 key rewards that could impact your investment decision.
- Our free Insulet research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Insulet's overall financial health at a glance.
Ready To Venture Into Other Investment Styles?
These stocks are moving-our analysis flagged them today. Act fast before the price catches up:
- Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.
- Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com